Nicotinamide Riboside (NR): The NAD+ Precursor With the Most Human Trial Data

Nicotinamide Riboside (NR): The NAD+ Precursor With the Most Human Trial Data

Nicotinamide Riboside (NR) is a form of vitamin B3 and one of the most studied NAD+ precursors in human clinical research. It entered the supplement market in 2013 following foundational work by Charles Brenner's lab at the University of Iowa, and has since accumulated a larger body of human pharmacokinetic and biomarker data than any other NAD+ precursor, including NMN. What that data actually shows — and where it falls short — is the subject of this guide.

What Is Nicotinamide Riboside?

NR is a pyridine-nucleoside form of niacin (vitamin B3). It is a naturally occurring compound found in trace amounts in milk and certain foods, though dietary amounts are far below those used in research. In the body, NR is phosphorylated by NR kinases (NRK1 and NRK2) to form NMN (nicotinamide mononucleotide), which is then adenylylated to form NAD+.

NAD+ is a central coenzyme in cellular energy metabolism and a required substrate for sirtuins (SIRT1–7), PARP enzymes involved in DNA repair, and CD38 — an enzyme implicated in NAD+ decline with age. Human NAD+ levels fall roughly 40–60% between young adulthood and mid-life, a decline linked to mitochondrial dysfunction, reduced metabolic efficiency, and impaired DNA repair capacity. NR's primary research rationale is restoring this deficit.

Molecular Profile

Mechanism of Action

NR enters cells and tissues via nucleoside transporters. Once intracellular, NRK1 (ubiquitous) and NRK2 (muscle/cardiac-enriched) phosphorylate NR to NMN. NMN is then converted to NAD+ by NMNAT enzymes (three isoforms, each localized to different compartments: cytoplasm, nucleus, and mitochondria).

Elevated intracellular NAD+ affects several downstream systems:

Sirtuin activation. Sirtuins are NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis (via SIRT1/PGC-1α), fatty acid oxidation, and stress responses. SIRT3 in particular regulates mitochondrial protein acetylation and is implicated in metabolic aging.

PARP activity. PARP1 and PARP2 consume NAD+ during DNA strand-break repair. Elevated NAD+ supports this repair capacity; conversely, chronic PARP activation can deplete NAD+ and impair sirtuin function — a cycle NR supplementation is proposed to interrupt.

CD38 inhibition (indirect). CD38 is the dominant NADase in mammals and its expression increases with age and inflammation. While NR does not directly inhibit CD38, raising NAD+ production may partially compensate for CD38-driven losses.

Mitochondrial biogenesis. In rodent models, NR activates SIRT1-mediated deacetylation of PGC-1α, upregulating mitochondrial gene expression and increasing mitochondrial number and function. This pathway is the basis for most of NR's metabolic claims.

What the Research Actually Shows

Pharmacokinetics and NAD+ Elevation (Human Data)

The most reliable NR finding in humans is that it dose-dependently raises whole-blood NAD+ and related metabolites. Key trials:

Trammell et al. (2016, Nature Communications): First controlled human pharmacokinetic study. 12 healthy adults received single doses of 100 mg, 300 mg, or 1,000 mg NR chloride. All doses raised blood NAD+ and metabolites; the 1,000 mg dose produced a mean ~2.7-fold rise in whole-blood NAD+ over baseline at peak. No serious adverse effects observed.

Dollerup et al. (2018, Nature Communications): 12-week RCT in 40 obese men. 2,000 mg/day NR significantly raised skeletal muscle NAD+ by ~100%. Despite robust NAD+ elevation, no statistically significant changes were observed in insulin sensitivity (primary endpoint), body composition, or skeletal muscle mitochondrial function compared to placebo. This is a critical finding — NAD+ elevation does not automatically translate to metabolic benefit in humans.

Elhassan et al. (2019, Cell Reports): 12-week crossover in 12 sedentary, overweight older men. 1,000 mg/day NR raised skeletal muscle NAD+ ~30% and upregulated SIRT1 target gene expression. Some markers of muscle mitochondrial function improved, but the study was small and the clinical significance is unclear.

Cardiovascular and Blood Pressure

Martens et al. (2018, Nature Communications): 12-week RCT in 30 healthy middle-aged and older adults. 500 mg twice daily NR reduced systolic blood pressure by a mean of ~10 mmHg in participants with elevated baseline blood pressure (≥120 mmHg). Aortic stiffness (measured by carotid-femoral pulse wave velocity) was also reduced. This is one of the more compelling human findings, though replication in larger trials is needed.

Mehmel et al. (2020, meta-analysis): Review of available cardiovascular NR data found consistent signals for blood pressure reduction in older/hypertensive populations, but inconsistent effects in normotensive younger subjects.

Cognitive and Neurological Research

Preclinical data in mice shows NR crosses the blood-brain barrier, raises brain NAD+, and reduces neuroinflammation in models of Alzheimer's and Parkinson's disease. Human data is minimal. One small pilot trial (12 weeks, 24 subjects with mild cognitive impairment, Gong et al.) found NR 1,000 mg/day raised CSF NAD+ and metabolites and showed trends toward reduced neuroinflammation biomarkers, but was not powered for cognitive endpoints. Larger trials are ongoing.

Muscle and Physical Performance

The 2018 Dollerup trial (mentioned above) found no effect on physical performance despite muscle NAD+ doubling. A 2020 trial by Remie et al. (Cell Metabolism, 12 weeks, 1,000 mg/day in overweight sedentary adults) similarly found NR raised muscle NAD+ substantially but had no effect on mitochondrial function measured by respirometry or substrate oxidation rates. These null results in muscle function are consistent across multiple trials and suggest that NAD+ elevation alone may be insufficient in the absence of additional stimuli (e.g., exercise).

Aging Biomarkers

A 2023 trial (Liao et al., published in GeroScience, n=66 healthy older adults, 6-month duration) found 600 mg/day NR raised NAD+ but did not significantly affect biological age clocks (Horvath, GrimAge) compared to placebo. Telomere length was unchanged. Inflammation markers (IL-6, TNF-α) were modestly reduced in the NR group but did not reach significance after correction for multiple comparisons.

Comparison to Other NAD+ Precursors

NR and NMN produce broadly similar NAD+ elevations in human blood at comparable doses. Head-to-head data is limited; one small crossover (Trammell et al.) found NR more efficiently converted to blood NAD+ than equivalent NMN doses, but methodological differences limit conclusions.

Research Limitations

Several caveats apply to NR research:

Whole-blood vs. tissue NAD+. Most human trials measure NAD+ in blood, not the tissues most relevant to longevity (liver, brain, skeletal muscle). Blood NAD+ elevation may not accurately reflect intracellular availability in target tissues.

Short trial duration. Most RCTs run 6–12 weeks. Whether sustained supplementation produces long-term functional benefits is unknown.

Healthy vs. deficient populations. Many trials enroll healthy middle-aged adults with normal baseline NAD+. Populations with actual NAD+ deficiency (elderly, metabolically compromised) may show larger functional effects, but this is understudied.

Biomarkers without clinical endpoints. Even when NR robustly raises NAD+ and surrogate markers, hard clinical outcomes — cardiovascular events, cognitive decline, functional aging — have not been studied. This gap is the central unresolved question.

Sponsor involvement. Several key trials were conducted with ChromaDex (NR patent holder) involvement or funding. Independent replication of positive findings remains limited.

CD38 and NAD+ consumers. In inflammatory or aged tissues, CD38 activity is so elevated that NR supplementation may be insufficient to meaningfully restore NAD+. Combining NR with CD38 inhibitors (e.g., apigenin, quercetin) is a hypothesis with limited human data.

Key Takeaways

1. NR is the most clinically studied NAD+ precursor, with consistent pharmacokinetic evidence that it raises whole-blood NAD+ in humans at doses of 300–2,000 mg/day.
2. The most robust functional finding in humans is blood pressure reduction (~10 mmHg systolic) in older adults with elevated baseline BP — seen in at least one replicated RCT.
3. Despite consistent NAD+ elevation, multiple well-designed RCTs have found no significant effect on insulin sensitivity, skeletal muscle mitochondrial function, or physical performance in overweight or sedentary adults.
4. Cognitive and neurological benefits are promising in preclinical models but are not established in humans. Trials in MCI populations are ongoing.
5. NR and NMN produce similar NAD+ elevations; no large head-to-head trial has demonstrated a clinically meaningful advantage for either.
6. Long-term safety at standard doses (300–1,000 mg/day) appears favorable based on available trial data. The most common reported side effects are mild GI discomfort and nausea at higher doses.
7. The central gap in NR research is the absence of hard clinical outcome data — no trial has yet shown that NAD+ elevation via NR translates to reduced disease incidence, extended healthspan, or delayed functional decline in humans.

This article is for informational and research reference purposes only. Nicotinamide Riboside is a commercially available dietary supplement; however, the longevity and performance claims discussed here are based on early-phase research and should not be interpreted as established therapeutic benefits. Consult a qualified healthcare provider before making supplementation decisions.